New Antibody Conjugates in Cancer Therapy by Serengulam V. Govindan, David M. Goldenberg

“…The area of drug-conjugated antibodies is progressing with encouraging data published for the trastuzumab-DM1 conjugate in a phase I clinical trial in HER2-positive breast cancer. …”
Get full text

Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country by Gabriela Pataccini, Andrés Elia, Gonzalo Sequeira, Luisa Ambrosio, Marcela Coianis, Caroline A. Lamb, Paola A. Rojas, Paula Martínez Vázquez, Javier Burruchaga, Eunice Spengler, Silvia I. Vanzulli, Martin Abba, Claudia Lanari

“…BC-AR474 was inhibited by trastuzumab and trastuzumab emtansine. BC-AR485 was sensitive to doxorubicin and resistant to paclitaxel in vivo and ex vivo. …”
Get full text

Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application by Kaichun Li, Jin Li

“…Due to the molecular study of gastric cancer, new molecular targeted drugs have entered the clinical use. Trastuzumab, an antibody targeting human epidermal growth factor receptor 2 (HER2), can significantly improve survival in advanced gastric cancer patients with HER2 overexpression. …”
Get full text

An Optimal Algorithm for Determining Risk Factors for Complex Diseases: Depressive Disorder, Osteoporosis, and Fracture in Young Patients with Breast Cancer Receiving Curative Surg... by Chieh-Yu Liu, Chun-Hung Chang

“…The results revealed that depressive disorder, osteoporosis, and fracture were clustered with liver cirrhosis, chronic obstructive pulmonary disease (COPD), distant metastasis, and primary metastatic and adjuvant therapies, namely, chemotherapy, radiotherapy, tamoxifen, aromatase inhibitors, and trastuzumab. Among the risk factors identified using this novel algorithm, liver cirrhosis and COPD have been rarely mentioned in the literature. …”
Get full text

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs by Xiang Zhang, Yulian Yin, Qiuting Yu, Xinlin Chen, Yiqin Cheng

“…Targeted therapeutic agents, represented by trastuzumab, have been effective in improving the survival rate of HER-2-positive breast cancer patients. …”
Get full text

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces by W. van der Wulp, W. Luu, M. E. Ressing, J. Schuurman, S. I. van Kasteren, L. Guelen, R. C. Hoeben, B. Bleijlevens, M. H. M. Heemskerk

“…AECs carrying epitopes genetically fused at the N-terminus of the light chains of cetuximab and trastuzumab demonstrate an even more efficient delivery of the T-cell epitopes compared to AECs with the epitope fused to the C-terminus of the heavy chain. …”
Get full text

Characterization of Somatic Mutations in Malaysian Luminal Breast Cancer by Yock Ping Chow, Ryia Illani Mohd Yunos, Isa Mohd Rose, Norlia Abdullah, Rohaizak Muhammad, Shahrun Niza Abdullah Suhaimi, Saladina Jaszle Jasmin, Norshahidah Mahamad Nadzir, Nurul-Syakima Ab Mutalib, Rahman Jamal

“…To date, other than hormonal and anti-HER2 therapies (e.g. tamoxifen, aromatase inhibitor, trastuzumab), no other targeted therapies have been approved by FDA for luminal breast cancer. …”
Get full text

Immediate-Early Genes and Delayed Primary Response Genes Regulated by NmU in SKBR3 HER-2 Positive Breast Cancer Cell Line by Jessica Murphy, Sweta Rani

“…Although survival rates have dramatically increased due to the development of Trastuzumab in 1997, many patients develop a resistance to this therapeutic treatment and relapse over time. …”
Get full text

Tumor-specific cytosol-penetrating antibodies for antigen- and TME-dependent intracellular cargo delivery by Carolin Sophie Dombrowsky, Felix Klaus Geyer, Diana Zakharchuk, Harald Kolmar

“…The relevance of the antigen-specific binding, internalization, and cytosolic cargo delivery was demonstrated in several in vitro assays using different cell lines with anti-B7-H3 scFv, the well-characterized trastuzumab (HER2), and inotuzumab (CD22) as examples. …”
Get full text

Antibodies to watch in 2024 by Silvia Crescioli, Hélène Kaplon, Alicia Chenoweth, Lin Wang, Jyothsna Visweswaraiah, Janice M. Reichert

“…These nearly 50 product candidates include numerous innovative bispecific antibodies, such as odronextamab, ivonescimab, linvoseltamab, zenocutuzumab, and erfonrilimab, and antibody–drug conjugates, such as trastuzumab botidotin, patritumab deruxtecan, datopotamab deruxtecan, and MRG002, as well as a mixture of two immunocytokines (bifikafusp alfa and onfekafusp alfa). …”
Get full text

Six events that shaped antibody approvals in oncology by Suman Paul, Suman Paul, Shibin Zhou, Shibin Zhou

“…We examine the circumstances that led to the approval of rituximab and trastuzumab, the first successful antibodies for the treatment of hematologic and solid cancers. …”
Get full text

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy by Yan Zhang, Wenxuan Fan, Fei Su, Xiaoling Zhang, Yunyi Du, Weiling Li, Yangjun Gao, Wenqing Hu, Jun Zhao

“…Human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in gastric/gastroesophageal junction (G/GEJ) cancers, despite the initial success of HER2-targeted therapies, such as trastuzumab, resistance to these drugs has emerged as a major impediment to effective long-term treatment. …”
Get full text

Improving the N-glycosylation occupancy of plant-produced IgG1 by engineering the amino acid environment at Asn297 by Kathrin Göritzer, Valentina Ruocco, Ulrike Vavra, Shiva Izadi, Omayra C. Bolaños-Martínez, Thareeya Phetphoung, Nuttapat Pisuttinusart, Waranyoo Phoolcharoen, Richard Strasser

“…The transient expression of trastuzumab and SARS-CoV-2 neutralizing IgG1 antibody COVA2-15 in N. benthamiana, with mutations such as Y300L, resulted in a notable improvement in glycosylation occupancy. …”
Get full text

Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer by M. V. Sedova, M. A. Batov, V. S. Tretyak, A. A. Kolomeytseva, V. M. Khomyakov, N. N. Volchenko, A. A. Fedenko, A. D. Kaprin

“…International studies have shown the results of the use of targeted (ramucirumab, trastuzumab, pertuzumab), immune drugs (pembrolizumab, nivolumab, ipilimumab), S‑1 in combination with chemotherapy as part of the combined treatment of gastric and esophageal‑ gastric junction cancer. …”
Get full text

Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy by Patrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, Laetitia Petersen, Nicole Egli, Simone Popp, Catherine Regnier, Kirsten Richter, Andreas Katopodis, Christoph Huber

“…ANV419 also enhances the NK cell killing capacity and increases tumor growth inhibition when used alongside trastuzumab in a Her-2+ xenograft mouse model. In cynomolgus monkeys, the estimated half-life of ANV419 is 24 h, and doses that induced sustained expansion of effector cells were well tolerated without the severe toxicities typically observed with high-dose IL-2. …”
Get full text

Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers by Femke A. I. Ehlers, Katie E. Blise, Courtney B. Betts, Shamilene Sivagnanam, Loes F. S. Kooreman, E. Shelley Hwang, Gerard M. J. Bos, Lotte Wieten, Lisa M. Coussens

“…Owing to the clinical evidence supporting a significant role for NK cells in HER2+ breast cancer in mediating responses to Trastuzumab, we further evaluated HER2- and HER2+ specimens separately. …”
Get full text

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies by Wen-Ting K. Tsai, Yinyin Li, Zhaojun Yin, Peter Tran, Qui Phung, Zhenru Zhou, Kun Peng, Dan Qin, Sien Tam, Christoph Spiess, Jochen Brumm, Manda Wong, Zhengmao Ye, Patrick Wu, Sivan Cohen, Paul J. Carter

“…Comparable or slightly higher immunogenicity risk assessment data were obtained for research-grade preparations of trastuzumab and bevacizumab versus Herceptin and Avastin, respectively. …”
Get full text

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors by Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B. Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra

“…In the HER2-low group, Sacituzumab govitecan and trastuzumab deruxtecan had a similar efficacy (HR, 95% CI): PFS (0.98; 0.63–1.43) and OS (1.08; 0.76–1.55). …”
Get full text

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

“…Results: All patients were diagnosed with a metastatic adenocarcinoma, had previously progressed on at least one line of chemotherapy and had been previously treated with trastuzumab-deruxtecan (two had to stop treatment because of pneumonitis). …”
Get full text

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer by Lorenzo Castagnoli, Alma Franceschini, Valeria Cancila, Matteo Dugo, Martina Bigliardi, Claudia Chiodoni, Paolo Toneguzzo, Viola Regondi, Paola A. Corsetto, Filippo Pietrantonio, Serena Mazzucchelli, Fabio Corsi, Antonio Belfiore, Antonio Vingiani, Giancarlo Pruneri, Francesca Ligorio, Mario P. Colombo, Elda Tagliabue, Claudio Tripodo, Claudio Vernieri, Tiziana Triulzi, Serenella M. Pupa

“…In addition, expression of CD36 in intratumor HER2 + mesenchymal CSCs is significantly associated with resistance to trastuzumab in HER2 + BC patients. Conclusions These results support the metabolo-oncogenic nature of CD36-mediated FA uptake in HER2 + therapy-refractory BC. …”
Get full text